{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:12:22Z","timestamp":1793142742053,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14619-7","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:27:57Z","timestamp":1777879677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy"],"prefix":"10.1186","volume":"26","author":[{"given":"Carla","family":"Rognoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Loseto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Frustaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Armeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"14619_CR1","volume-title":"Advancements in Cancer Research","author":"LM Wainman","year":"2023","unstructured":"Wainman LM, Khan WA, Kaur P. Chronic Lymphocytic Leukemia: Current Knowledge and Future Advances in Cytogenomic Testing. In: Sergi CM, editor. Advancements in Cancer Research. Brisbane (AU): Exon; 2023."},{"key":"14619_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/annonc\/mdw547","volume":"28","author":"R Stauder","year":"2017","unstructured":"Stauder R, Eichhorst B, Hamaker ME, Kaplanov K, Morrison VA, \u00d6sterborg A, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol. 2017;28:218\u201327. https:\/\/doi.org\/10.1093\/annonc\/mdw547.","journal-title":"Ann Oncol"},{"key":"14619_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3390\/cancers15051583","volume":"15","author":"P Iyer","year":"2023","unstructured":"Iyer P, Wang L. Emerging Therapies in CLL in the Era of Precision Medicine. Cancers (Basel). 2023;15:1583. https:\/\/doi.org\/10.3390\/cancers15051583.","journal-title":"Cancers (Basel)"},{"key":"14619_CR4","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1182\/blood-2023-188454","volume":"142","author":"L Scarfo","year":"2023","unstructured":"Scarfo L, Coscia M, Molteni A, Rambaldi A, Marasca R, Steffanoni S, et al. A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial. Blood. 2023;142:6544. https:\/\/doi.org\/10.1182\/blood-2023-188454.","journal-title":"Blood"},{"key":"14619_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40261-021-01044-3","volume":"41","author":"G Ronconi","year":"2021","unstructured":"Ronconi G, Dondi L, Calabria S, Piccinni C, Pedrini A, Esposito I, et al. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Na\u00efve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis. Clin Drug Investig. 2021;41:595\u2013604. https:\/\/doi.org\/10.1007\/s40261-021-01044-3.","journal-title":"Clin Drug Investig"},{"key":"14619_CR6","unstructured":"Imbruvica | European Medicines Agency (EMA). 2014. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imbruvica. Accessed 21 Apr 2025."},{"key":"14619_CR7","unstructured":"Venclyxto | European Medicines Agency (EMA). 2016. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/venclyxto. Accessed 21 Apr 2025."},{"key":"14619_CR8","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019;380:2095\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa1900574.","journal-title":"N Engl J Med"},{"key":"14619_CR9","unstructured":"Gazyvaro | European Medicines Agency (EMA). 2014. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gazyvaro. Accessed 21 Apr 2025."},{"key":"14619_CR10","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1182\/blood.2024024631","volume":"144","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924\u201335. https:\/\/doi.org\/10.1182\/blood.2024024631.","journal-title":"Blood"},{"key":"14619_CR11","unstructured":"MabThera | European Medicines Agency (EMA). 2009. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera. Accessed 21 Apr 2025."},{"key":"14619_CR12","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3324\/haematol.2018.189837","volume":"103","author":"A Cuneo","year":"2018","unstructured":"Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, et al. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018;103:1209\u201317. https:\/\/doi.org\/10.3324\/haematol.2018.189837.","journal-title":"Haematologica"},{"key":"14619_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/hon.2744","volume":"38","author":"A Panovsk\u00e1","year":"2020","unstructured":"Panovsk\u00e1 A, N\u011bmcov\u00e1 L, Nekvindov\u00e1 L, \u0160pa\u010dek M, \u0160imkovi\u010d M, Papaj\u00edk T, et al. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group. Hematol Oncol. 2020;38:509\u201316. https:\/\/doi.org\/10.1002\/hon.2744.","journal-title":"Hematol Oncol"},{"key":"14619_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/2040620716681749","volume":"8","author":"AP Skarbnik","year":"2017","unstructured":"Skarbnik AP, Faderl S. The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies. Ther Adv Hematol. 2017;8:99\u2013105. https:\/\/doi.org\/10.1177\/2040620716681749.","journal-title":"Ther Adv Hematol"},{"key":"14619_CR15","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(10)61381-5.","journal-title":"Lancet"},{"issue":"4 Suppl","key":"14619_CR16","first-page":"s99","volume":"22","author":"NJ Egerton","year":"2016","unstructured":"Egerton NJ. In-office dispensing of oral oncolytics: a continuity of care and cost mitigation model for cancer patients. Am J Manag Care. 2016;22(4 Suppl):s99\u2013103.","journal-title":"Am J Manag Care"},{"key":"14619_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2143\/ACB.66.2.2062525","volume":"66","author":"V Foulon","year":"2011","unstructured":"Foulon V, Sch\u00f6ffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg. 2011;66:85\u201396. https:\/\/doi.org\/10.2143\/ACB.66.2.2062525.","journal-title":"Acta Clin Belg"},{"key":"14619_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/030089161309900106","volume":"99","author":"S Gori","year":"2013","unstructured":"Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, et al. Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). Tumori. 2013;99:35\u20138. https:\/\/doi.org\/10.1177\/030089161309900106.","journal-title":"Tumori"},{"key":"14619_CR19","doi-asserted-by":"publisher","first-page":"E88","DOI":"10.1188\/14.CJON.E88-E92","volume":"18","author":"J Matthews","year":"2014","unstructured":"Matthews J, Caprera PH. Essentials of oral oncolytics: developing a nursing reference. Clin J Oncol Nurs. 2014;18:E88\u201392. https:\/\/doi.org\/10.1188\/14.CJON.E88-E92.","journal-title":"Clin J Oncol Nurs"},{"key":"14619_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/annonc\/mdp564","volume":"21","author":"F Stiefel","year":"2010","unstructured":"Stiefel F, Barth J, Bensing J, Fallowfield L, Jost L, Razavi D, et al. Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009. Ann Oncol. 2010;21:204\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdp564.","journal-title":"Ann Oncol"},{"key":"14619_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/14737167.2020.1764353","volume":"21","author":"M Altini","year":"2021","unstructured":"Altini M, Gentili N, Balzi W, Musuraca G, Maltoni R, Masini C, et al. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology. Expert Rev Pharmacoecon Outcomes Res. 2021;21:503\u20139. https:\/\/doi.org\/10.1080\/14737167.2020.1764353.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"14619_CR22","unstructured":"Conto Annuale. https:\/\/contoannuale.rgs.mef.gov.it\/. Accessed 1 Dec 2022."},{"key":"14619_CR23","unstructured":"Istat. - Rivaluta. https:\/\/rivaluta.istat.it\/. Accessed 27 Feb 2024."},{"key":"14619_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s40267-023-01038-5","volume":"39","author":"E Munzone","year":"2023","unstructured":"Munzone E, Fabi A, Buono G, Caputo R, Montagna E, Negri M, et al. The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2 + Breast Cancer Patients. Drugs Ther Perspect. 2023;39:432\u201346. https:\/\/doi.org\/10.1007\/s40267-023-01038-5.","journal-title":"Drugs Ther Perspect"},{"key":"14619_CR25","unstructured":"HTA Core Model 3.0 - EUnetHTA. 2016. https:\/\/www.eunethta.eu\/hta-core-model-3-0\/. Accessed 16 Dec 2024."},{"key":"14619_CR26","unstructured":"Monitoring Registers. https:\/\/www.aifa.gov.it\/en\/registri-farmaci-sottoposti-a-monitoraggio. Accessed 22 Apr 2025."},{"key":"14619_CR27","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.3390\/curroncol30050339","volume":"30","author":"J Lachaine","year":"2023","unstructured":"Lachaine J, Guinan K, Aw A, Banerji V, Fleury I, Owen C. Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada. Curr Oncol. 2023;30:4483\u201398. https:\/\/doi.org\/10.3390\/curroncol30050339.","journal-title":"Curr Oncol"},{"key":"14619_CR28","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.18553\/jmcp.2024.24049","volume":"30","author":"SF Huntington","year":"2024","unstructured":"Huntington SF, Manzoor BS, Jawaid D, Puckett JT, Emechebe N, Ravelo A, et al. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton\u2019s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting. J Manag Care Spec Pharm. 2024;30:1106\u201316. https:\/\/doi.org\/10.18553\/jmcp.2024.24049.","journal-title":"J Manag Care Spec Pharm"},{"key":"14619_CR29","unstructured":"Innovation for sustainable cancer care. https:\/\/www.efpia.eu\/about-medicines\/use-of-medicines\/disease-specific-groups\/fighting-cancer\/innovation-for-sustainable-cancer-care\/. Accessed 21 Apr 2025."},{"key":"14619_CR30","doi-asserted-by":"publisher","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. NEJM Evid. 2022;1:EVIDoa2200006. https:\/\/doi.org\/10.1056\/EVIDoa2200006.","journal-title":"NEJM Evid"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14619-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14619-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14619-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:57:29Z","timestamp":1782125849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14619-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14619"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14619-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As four hematologists completed a questionnaire about their clinical practice with no reference to specific patients, no critical ethical issues were identified, and formal ethics approval and consent to participate were not required under the Bocconi University Ethics Committee regulations. The research was not conducted on humans\/humans data so adherence to the Declaration of Helsinki is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (the manuscript does not contain data from any individual person).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Giacomo Loseto reports fees for consultancies\/participation into speakers\u2019 bureau or advisory board with Janssen-Cilag, Gilead, Roche, Italfarmaco, Takeda, AbbVie, Incyte, AstraZeneca, BeOne, GSK, Lilly. Antonio Cuneo reports fees for participation into speakers\u2019 bureau and advisory board with Abbvie, AstraZeneca, BeOne, Janssen and Lilly. Anna Maria Frustaci reports participation into advisory boards, congresses sponsorships, consultancies with BeOne, Janssen, Abbvie, AstraZeneca. The other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"865"}}